Entrada shareholders approve plan amendments including pre-funded warrants in evergreen formulas

Entrada Therapeutics, Inc.

Stockholders elected Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. as Class II directors; 22.2M and 22.3M votes for, respectively.
Ratified Ernst & Young as independent auditor for FY 2026 with 33.1M votes for.
Approved Amendment No. 1 to 2021 Stock Option and Incentive Plan: pre-funded warrants count in evergreen share increase calculation.
Approved Amendment No. 1 to 2021 ESPP: similarly includes pre-funded warrants in share reserve formula, plus share cap of 557,524 or 1% of outstanding shares.
38.8M shares outstanding as of record date; 33.2M shares represented at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Entrada Therapeutics, Inc. shareholders approved Approve Amendment No. 1 to the 2021 Employee Stock Purchase Plan (2021 ESPP Amendment) to modify the evergreen provision at the 2026-06-10 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

The 2021 ESPP Amendment was approved. The results of the stockholders’ vote with respect to such approval were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 16,780,217 7,475,514 3,730 8,930,773

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Entrada Therapeutics, Inc. shareholders approved Election of two Class II directors: Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were duly elected to the Board as Class II directors. The results of the stockholders’ vote with respect to the election were as follows: CLASS II DIRECTOR NOMINEES FOR WITHHELD BROKER NON-VOTES Peter S. Kim, Ph.D. 22,181,490 2,077,971 8,930,773 Bernhardt Zeiher, M.D. 22,315,323 1,944,138 8,930,773

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Entrada Therapeutics, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The results of the stockholders’ vote with respect to such ratification were as follows: FOR AGAINST ABSTAIN 33,132,550 49,650 8,034

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Entrada Therapeutics, Inc. shareholders approved Approve Amendment No. 1 to the 2021 Stock Option and Incentive Plan (2021 Plan Amendment) to modify the evergreen provision at the 2026-06-10 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

The 2021 Plan Amendment was approved. The results of the stockholders’ vote with respect to such approval were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 14,686,713 9,566,186 6,562 8,930,773

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-072326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.